Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actileucel - ActiTrexx

Next Previous
X
Search
Drug Profile

Actileucel - ActiTrexx

Alternative Names: Activated regulatory T cells - ActiTrexx; ATreg - ActiTrexx; CD4-mediated activated regulatory T cells - ActiTrexx; GP120-activated regulatory T cells - ActiTrexx

Latest Information Update: 05 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University Medical Center of the Johannes Gutenberg University Mainz
  • Developer ActiTrexx
  • Class Regulatory T lymphocyte cell therapies
  • Mechanism of Action Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Graft-versus-host disease

Most Recent Events

  • 19 Mar 2024 Phase-I/II clinical trials in Graft-versus-host disease (Prevention) in Germany (IV) prior to March 2024(EudraCT2021-006490-32) (EudraCT2024-516599-14-00)
  • 19 Mar 2024 Phase-I/II clinical trials in Graft-versus-host disease in Germany (IV) prior to March 2024(EudraCT2021-006490-32) (EudraCT2024-516599-14-00)
  • 27 Nov 2017 Actileucel receives Orphan Drug status for Graft-versus-host disease in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top